CN106810464B - L-鸟氨酸苯乙酸盐及其制备方法 - Google Patents

L-鸟氨酸苯乙酸盐及其制备方法 Download PDF

Info

Publication number
CN106810464B
CN106810464B CN201710053850.1A CN201710053850A CN106810464B CN 106810464 B CN106810464 B CN 106810464B CN 201710053850 A CN201710053850 A CN 201710053850A CN 106810464 B CN106810464 B CN 106810464B
Authority
CN
China
Prior art keywords
crystalline form
orn
salt
solution
phenyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710053850.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN106810464A (zh
Inventor
K·安德森
J·贝林
C·H·杜根
S·W·瓦特
P·玛尼尼
A·菲吉尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocera Therapeutics Inc
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Publication of CN106810464A publication Critical patent/CN106810464A/zh
Application granted granted Critical
Publication of CN106810464B publication Critical patent/CN106810464B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201710053850.1A 2009-04-03 2010-04-01 L-鸟氨酸苯乙酸盐及其制备方法 Active CN106810464B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16667609P 2009-04-03 2009-04-03
US61/166,676 2009-04-03
CN201080021311.6A CN102421432B (zh) 2009-04-03 2010-04-01 L-鸟氨酸苯乙酸盐及其制备方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080021311.6A Division CN102421432B (zh) 2009-04-03 2010-04-01 L-鸟氨酸苯乙酸盐及其制备方法

Publications (2)

Publication Number Publication Date
CN106810464A CN106810464A (zh) 2017-06-09
CN106810464B true CN106810464B (zh) 2019-01-22

Family

ID=42828717

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201710053850.1A Active CN106810464B (zh) 2009-04-03 2010-04-01 L-鸟氨酸苯乙酸盐及其制备方法
CN201410392027.XA Active CN104230730B (zh) 2009-04-03 2010-04-01 L‑鸟氨酸苯乙酸盐及其制备方法
CN201080021311.6A Active CN102421432B (zh) 2009-04-03 2010-04-01 L-鸟氨酸苯乙酸盐及其制备方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201410392027.XA Active CN104230730B (zh) 2009-04-03 2010-04-01 L‑鸟氨酸苯乙酸盐及其制备方法
CN201080021311.6A Active CN102421432B (zh) 2009-04-03 2010-04-01 L-鸟氨酸苯乙酸盐及其制备方法

Country Status (26)

Country Link
US (9) US8173706B2 (https=)
EP (4) EP3263100B1 (https=)
JP (6) JP6144488B2 (https=)
KR (6) KR102217081B1 (https=)
CN (3) CN106810464B (https=)
AU (1) AU2010232521B2 (https=)
BR (1) BRPI1013657A2 (https=)
CA (5) CA2998344C (https=)
CY (1) CY1119843T1 (https=)
DK (3) DK2413924T3 (https=)
EA (2) EA023051B1 (https=)
ES (3) ES2928586T3 (https=)
HR (2) HRP20221232T8 (https=)
HU (2) HUE035921T2 (https=)
IL (2) IL215449B (https=)
LT (2) LT3686183T (https=)
MX (4) MX356608B (https=)
NO (1) NO2413924T3 (https=)
NZ (3) NZ619235A (https=)
PL (2) PL2413924T3 (https=)
PT (2) PT2413924T (https=)
SG (3) SG174982A1 (https=)
SI (1) SI2413924T1 (https=)
SM (2) SMT202200395T1 (https=)
WO (1) WO2010115055A1 (https=)
ZA (1) ZA201107189B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2153870T1 (sl) 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
US8068011B1 (en) 2010-08-27 2011-11-29 Q Street, LLC System and method for interactive user-directed interfacing between handheld devices and RFID media
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
CN102993037B (zh) * 2012-11-20 2015-03-04 南京工业大学 一种l-鸟氨酸苯乙酸盐的制备方法
CN105481725B (zh) * 2014-09-18 2019-01-22 博瑞生物医药（苏州）股份有限公司 L-精氨酸苯乙酸盐的晶型及其制备方法
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
CN107708684A (zh) 2015-04-20 2018-02-16 欧塞拉治疗有限公司 L‑鸟氨酸苯乙酸盐制剂
WO2017031131A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
HK1257679A1 (zh) * 2015-09-25 2019-10-25 Ocera Therapeutics, Inc. 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CN108366983A (zh) 2015-11-13 2018-08-03 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐制剂
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
MX2020001765A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
SG11202111509PA (en) 2019-05-09 2021-11-29 Ocera Therapeutics Inc Methods of assessing and treating hepatic encephalopathy
CN110707221B (zh) * 2019-09-25 2023-09-01 北京大学深圳研究生院 氨基酸离子液体在制备钙钛矿光电器件中钙钛矿层的应用
PH12022550738A1 (en) * 2019-10-16 2023-05-08 Mallinckrodt Entpr Llc Dosages and uses of ornithine phenylacetate for treating hyperammonemia
WO2023240081A1 (en) * 2022-06-06 2023-12-14 Yale University Treatment, amelioration, and/or prevention of inflammatory and autoimmune diseases
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03009902A (es) * 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
CN102512408A (zh) * 2004-11-26 2012-06-27 Ucl商业有限公司 用于治疗肝性脑病的含有鸟氨酸和苯基乙酸或苯基丁酸的组合物

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (https=) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4100293A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US4857555A (en) 1985-09-12 1989-08-15 Brigham & Women's Hospital Method of treating catabolic dysfunction
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
JP2522034B2 (ja) 1988-12-27 1996-08-07 味の素株式会社 α−ケト酸・アミノ酸塩化合物及びその製造方法
JPH03273578A (ja) 1990-03-23 1991-12-04 Ricoh Co Ltd 対物レンズクリーニング装置
DE4020980C1 (https=) * 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
JP3166123B2 (ja) 1992-09-09 2001-05-14 フアイソンズ・ピーエルシー 薬剤パッケージング
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5840891A (en) 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
WO1997030167A1 (en) 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
CA2374273A1 (en) 1999-05-21 2000-11-30 Takeda Chemical Industries, Ltd. Liver function controlling agents
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
JPWO2002074302A1 (ja) 2001-03-15 2005-07-14 独立行政法人理化学研究所 肝機能障害改善用アミノ酸組成物
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
JPWO2004019928A1 (ja) 2002-08-30 2005-12-15 味の素株式会社 肝疾患治療剤
US20050059150A1 (en) * 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
CA2556752C (en) * 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7589235B2 (en) * 2004-05-06 2009-09-15 Osteologix, A/S High yield and rapid synthesis methods for producing metallo-organic salts
WO2006059237A1 (en) 2004-08-30 2006-06-08 Lunamed, Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
HRP20140476T1 (hr) 2005-11-17 2014-07-18 Silverstone Pharma Est. Stabilni oblik amorfnih soli perindoprila, postupak njihove pripreme, posebno industrijske pripreme i njihova uporaba u lijeäśenju hipertenzije
JPWO2007077995A1 (ja) 2006-01-05 2009-06-11 協和発酵バイオ株式会社 筋肉増量剤
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
WO2009149196A1 (en) 2008-06-04 2009-12-10 Phenolics, Llc. Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
JP2011236160A (ja) 2010-05-11 2011-11-24 Shinshu Univ 非アルコール性肝疾患治療薬
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
PT2922576T (pt) 2012-11-21 2018-01-24 Horizon Therapeutics Llc Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática
CN103705490B (zh) 2013-10-31 2016-08-17 蚌埠丰原医药科技发展有限公司 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
CN107708684A (zh) 2015-04-20 2018-02-16 欧塞拉治疗有限公司 L‑鸟氨酸苯乙酸盐制剂
WO2017031131A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
HK1257679A1 (zh) 2015-09-25 2019-10-25 Ocera Therapeutics, Inc. 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
SG11202111509PA (en) 2019-05-09 2021-11-29 Ocera Therapeutics Inc Methods of assessing and treating hepatic encephalopathy
PH12022550738A1 (en) 2019-10-16 2023-05-08 Mallinckrodt Entpr Llc Dosages and uses of ornithine phenylacetate for treating hyperammonemia
EP4153162A4 (en) 2020-05-22 2024-06-05 Ocera Therapeutics, Inc. USES OF ORNITHINE PHENYLACETATE FOR THE TREATMENT OF HYPERAMMONEMIA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03009902A (es) * 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
CN102512408A (zh) * 2004-11-26 2012-06-27 Ucl商业有限公司 用于治疗肝性脑病的含有鸟氨酸和苯基乙酸或苯基丁酸的组合物

Also Published As

Publication number Publication date
JP2015145372A (ja) 2015-08-13
KR20180033313A (ko) 2018-04-02
US20120208885A1 (en) 2012-08-16
CA2998434C (en) 2020-05-12
EP3686183B1 (en) 2022-08-03
EA201171216A1 (ru) 2012-05-30
AU2010232521B2 (en) 2015-07-16
HUE035921T2 (en) 2018-05-28
KR20190068561A (ko) 2019-06-18
US20220162155A1 (en) 2022-05-26
SMT201700601T1 (it) 2018-03-08
SG174982A1 (en) 2011-11-28
US20180044281A1 (en) 2018-02-15
DK2413924T3 (en) 2017-12-11
IL215449B (en) 2019-01-31
EA034409B1 (ru) 2020-02-05
CY1119843T1 (el) 2018-06-27
US8173706B2 (en) 2012-05-08
US8492439B2 (en) 2013-07-23
SMT202200395T1 (it) 2022-11-18
DK3686183T3 (da) 2022-10-03
EP3263100A1 (en) 2018-01-03
CA2757373C (en) 2018-05-08
CA3077846A1 (en) 2010-10-07
US10550069B2 (en) 2020-02-04
IL263784A (en) 2019-01-31
LT2413924T (lt) 2018-02-12
AU2010232521A1 (en) 2011-11-17
HK1248558A1 (en) 2018-10-19
CN104230730B (zh) 2017-05-24
CA3077846C (en) 2023-08-22
SG10201406300YA (en) 2015-01-29
JP7086118B2 (ja) 2022-06-17
MX388894B (es) 2025-03-20
IL215449A0 (en) 2011-12-29
CA2998344C (en) 2020-06-02
EA023051B1 (ru) 2016-04-29
EA201500650A1 (ru) 2015-10-30
MX2020009699A (es) 2021-12-17
JP2020100624A (ja) 2020-07-02
ES2928586T3 (es) 2022-11-21
EP2413924A1 (en) 2012-02-08
HUE060371T2 (hu) 2023-02-28
JP2012522803A (ja) 2012-09-27
CA2998344A1 (en) 2010-10-07
PT2413924T (pt) 2018-01-04
US10173964B2 (en) 2019-01-08
CN102421432A (zh) 2012-04-18
JP2018138575A (ja) 2018-09-06
CN106810464A (zh) 2017-06-09
US20150251990A1 (en) 2015-09-10
US11161802B2 (en) 2021-11-02
US8785498B2 (en) 2014-07-22
PL3686183T3 (pl) 2022-11-28
CN104230730A (zh) 2014-12-24
CA3205755A1 (en) 2010-10-07
HRP20221232T8 (hr) 2023-02-03
ES2791524T3 (es) 2020-11-04
JP6144488B2 (ja) 2017-06-07
KR102123243B1 (ko) 2020-06-17
MX2011010262A (es) 2012-01-25
EP4101838A1 (en) 2022-12-14
ES2652187T3 (es) 2018-01-31
ZA201107189B (en) 2012-12-27
CA2998434A1 (en) 2010-10-07
HRP20221232T1 (hr) 2022-12-23
EP2413924A4 (en) 2013-01-02
BRPI1013657A2 (pt) 2016-04-26
SI2413924T1 (en) 2018-01-31
KR101975726B1 (ko) 2019-05-07
NO2413924T3 (https=) 2018-02-24
US20180319736A1 (en) 2018-11-08
DK3263100T3 (da) 2020-05-11
KR20210019592A (ko) 2021-02-22
JP6647336B2 (ja) 2020-02-14
JP2017081940A (ja) 2017-05-18
NZ708458A (en) 2017-02-24
NZ619235A (en) 2015-06-26
HRP20171962T1 (hr) 2018-02-09
SG10202010988WA (en) 2020-12-30
CN102421432B (zh) 2014-09-17
US12516015B2 (en) 2026-01-06
NZ595706A (en) 2014-01-31
US20100280119A1 (en) 2010-11-04
KR20220067001A (ko) 2022-05-24
WO2010115055A1 (en) 2010-10-07
MX356608B (es) 2018-06-06
KR20120006039A (ko) 2012-01-17
KR20200070438A (ko) 2020-06-17
US20130296429A1 (en) 2013-11-07
JP6328737B2 (ja) 2018-05-23
CA2757373A1 (en) 2010-10-07
US9604909B2 (en) 2017-03-28
JP6010154B2 (ja) 2016-10-19
KR102217081B1 (ko) 2021-02-18
EP3263100B1 (en) 2020-04-01
PT3686183T (pt) 2022-10-03
JP2022088504A (ja) 2022-06-14
US9034925B2 (en) 2015-05-19
KR101844605B1 (ko) 2018-04-02
EP3686183A1 (en) 2020-07-29
MX375111B (es) 2025-03-06
US20140288327A1 (en) 2014-09-25
PL2413924T3 (pl) 2018-02-28
KR102399540B1 (ko) 2022-05-17
EP2413924B1 (en) 2017-09-27
LT3686183T (lt) 2022-11-10
US20200239406A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
CN106810464B (zh) L-鸟氨酸苯乙酸盐及其制备方法
AU2015221466B2 (en) L-ornithine phenyl acetate and methods of making thereof
HK1248558B (en) L-ornithine phenyl acetate and methods of making thereof
HK1166699A (en) L-ornithine phenyl acetate and methods of making thereof
HK1166699B (en) L-ornithine phenyl acetate and methods of making thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant